Compare SCKT & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCKT | MIRA |
|---|---|---|
| Founded | 1992 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 43.7M |
| IPO Year | 1996 | 2023 |
| Metric | SCKT | MIRA |
|---|---|---|
| Price | $0.83 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.8K | ★ 99.7K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,078,332.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.82 | $0.90 |
| 52 Week High | $1.36 | $2.45 |
| Indicator | SCKT | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.48 | 41.69 |
| Support Level | N/A | $0.91 |
| Resistance Level | $1.09 | $1.24 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 1.18 | 24.72 |
Socket Mobile Inc is a producer of data capture products. The company's products are integrated into mobile applications used in mobile point of sale (mPOS), commercial services (field workers), asset tracking, manufacturing process and quality control, transportation and logistics (goods tracking and movement), event management (ticketing, entry, access control, and identification), medical and education. The company offers barcode scanning products for both one-dimensional, including imager and laser, and two-dimensional barcode scanning in standard and durable cases. The company's geographical segments are the Americas, Europe, Asia Pacific, and Africa, of which the majority of the revenue is generated from the United States.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.